New psoriasis drug aims to match leading treatment
NCT ID NCT06398652
Summary
This study is testing if a new drug called CMAB015 works as well as an already approved drug, secukinumab, for adults with moderate to severe plaque psoriasis. About 336 participants will receive injections of one of the two drugs for a year to see which is better at clearing skin and is safer. The main goal is to see if the new drug helps the same percentage of people achieve a 75% improvement in their psoriasis.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huashan Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.